(Q33358752)

26 July 2017

1 reference

title

Clinical pharmacokinetics of everolimus (English)

1 reference

26 July 2017

1 reference

Gabriele I Kirchner

1

1 reference

26 July 2017

Ivo Meier-Wiedenbach

series ordinal

2

1 reference

26 July 2017

Michael P Manns

series ordinal

3

1 reference

26 July 2017

publication date

1 January 2004

1 reference

Clinical Pharmacokinetics

26 July 2017

published in

1 reference

26 July 2017

volume

43

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

83-95

1 reference

The role of Certican (everolimus, rad) in the many pathways of chronic rejection

26 July 2017

cites work

1 reference

12 December 2020

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine

1 reference

12 December 2020

Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus

1 reference

12 December 2020

The future role of target of rapamycin inhibitors in renal transplantation

1 reference

12 December 2020

Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine.

1 reference

12 December 2020

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

1 reference

12 December 2020

TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.

1 reference

12 December 2020

Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of an SDZ-RAD 17,18,19,20,21,22-tris-epoxide

1 reference

12 December 2020

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment

1 reference

12 December 2020

Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry.

1 reference

12 December 2020

Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants

1 reference

12 December 2020

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

1 reference

12 December 2020

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

1 reference

12 December 2020

Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry

1 reference

12 December 2020

Rapamycin for immunosuppression in organ allografting.

1 reference

12 December 2020

Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications

1 reference

12 December 2020

The evolving role of tor inhibitors for individualizing posttransplant immunosuppression

1 reference

12 December 2020

Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients

1 reference

12 December 2020

Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling

1 reference

12 December 2020

Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients

1 reference

12 December 2020

Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.

1 reference

12 December 2020

RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis

1 reference

12 December 2020

Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation

1 reference

12 December 2020

The synergistic effects of cyclosporine and sirolimus

1 reference

12 December 2020

Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes

1 reference

12 December 2020

Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients

1 reference

12 December 2020

Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.

1 reference

12 December 2020

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

1 reference

12 December 2020

Immunopharmacology of rapamycin

1 reference

12 December 2020

Simultaneous quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid chromatography-mass spectrometry (LC-MS).

1 reference

12 December 2020

Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants

1 reference

12 December 2020

Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.

1 reference

12 December 2020

Early clinical experience with a novel rapamycin derivative

1 reference

12 December 2020

Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells

1 reference

12 December 2020

Current immunosuppressant regimens: considerations for critical care

1 reference

12 December 2020

Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis

1 reference

12 December 2020

Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization

1 reference

12 December 2020

LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood

1 reference

12 December 2020

Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD

1 reference

12 December 2020

Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction

1 reference

12 December 2020

Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin

1 reference

12 December 2020

Everolimus in pediatric de nova renal transplant patients

1 reference

12 December 2020

Progress in the clinical application of immunosuppressive drugs in renal transplantation

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

1 reference

12 December 2020

Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats

1 reference

12 December 2020

Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology.

1 reference

12 December 2020

Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood.

1 reference

12 December 2020

Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients

1 reference

12 December 2020

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

1 reference

12 December 2020

High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system

1 reference

12 December 2020

Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats

1 reference

12 December 2020

Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin

1 reference

12 December 2020

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.

1 reference

12 December 2020

Effect of rifampin on apparent clearance of everolimus

1 reference

12 December 2020

Everolimus. Novartis.

1 reference

12 December 2020

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

1 reference

12 December 2020

Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection

1 reference

12 December 2020

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

1 reference

12 December 2020

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

1 reference

12 December 2020

Chemical modification of rapamycin: the discovery of SDZ RAD.

1 reference

12 December 2020

In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin

1 reference

12 December 2020

High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood

1 reference

12 December 2020

Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription

1 reference

12 December 2020

Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation

1 reference

12 December 2020

Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide

1 reference

12 December 2020

Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine

1 reference

12 December 2020

The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation.

1 reference

12 December 2020

In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry

1 reference

12 December 2020

Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.2165/00003088-200443020-00002

1 reference

Dimensions Publication ID

26 July 2017

1000821215

0 references

1 reference